Goetz MP, O'Shaughnessy J, Sledge Jr., et al. The benefit of abemaciclib in prognostic subgroups: An exploratory analysis of combined data from the MONARCH 2 and 3 studies. SABCS 2017, GS6-02.
OLVG start met immunotherapie voor long- en niercelkanker
jul 2017 | Longoncologie, Uro-oncologie